If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles. With the S&P 500 trading at rich multiples and earnings expectations leaning heavily on tech, investors hunting for under-the-radar names near $50 a share have a reason to look at oncology specialists with real cash flow rather than speculative pipeline-only biotechs.

With that in mind, here is one biotech stock trading near $50 that fits the profile of a defensive growth name analysts believe still has room to run.

Exelixis (NASDAQ: EXEL)

Exelixis (NASDAQ:EXEL | EXEL Price Prediction) is an oncology-focused biotechnology company headquartered in Alameda, California, that discovers and commercializes targeted cancer therapies, most notably CABOMETYX in kidney, liver, and thyroid cancers.

Shares trade near $50, after a 12.05% gain over the past month and a 14.15% year-to-date advance. For a retail investor, that price point still buys a profitable mid-cap biotech with a $12.58 billion market capitalization rather than a speculative clinical-stage name.

Fundamentals back up the price action. Q1 2026 non-GAAP EPS came in at $0.87, beating consensus by 14.02%, on revenue of $610.81 million, up 9.97% year over year. Operating income jumped 34.51% and net income climbed 31.86%. That marks four consecutive earnings beats with surprise margins between 14.02% and 17.17%.

The stock trades at a trailing P/E of 17 and a forward P/E of 16, with an analyst target price of $49.65 reflecting one strong buy, nine buy, and nine hold ratings. H.C. Wainwright carries a $54 price target with a Buy rating.

The bull case is straightforward. CABOMETYX is the number one prescribed TKI in renal cell carcinoma, and global cabozantinib franchise revenue grew 12.5% year over year to $764 million in Q1. Management is sitting on roughly $1.4 billion in cash and marketable securities and just authorized a new $750 million buyback running through December 31, 2027, on top of completing the prior $750 million program. Layered on top is the December 3, 2026 PDUFA date for zanzalintinib in previously treated metastatic colorectal cancer, an indication CEO Michael Morrissey called “the top priority for the entire Exelixis, Inc. organization,” with a market opportunity management pegs at approximately $1.5 billion. FY2026 guidance of $2.525 billion to $2.625 billion in total revenue explicitly excludes any zanzalintinib launch contribution, leaving room for upside.

The key risk is concentration. The cabozantinib franchise still generates the overwhelming majority of revenue, and a regulatory delay or rejection of zanzalintinib would remove the most-watched near-term catalyst. Clinical disappointments, such as the LightSpark-012 readout management referenced, are a reminder that “triplet therapy in clear cell renal cell carcinoma is not an easy game.” Generic pressure on cabozantinib later this decade also looms.

With a beta of 0.385, profitable operations, an aggressive buyback, and a binary catalyst landing in December, EXEL looks like the kind of cash-generative oncology name that historically benefits when defensive healthcare comes back into favor.

A share price near $50 is a frame of reference, not a thesis. Concentration risk, FDA outcomes, and broader sector rotation can all move quickly, so readers should treat this as a starting point for their own due diligence rather than a recommendation, and size any position around their own risk tolerance and time horizon.